Thrombodyne, Inc.

Salt Lake City, UT 84103

SBIR Award Summary

Total Number of Awards 13
Total Value of Awards $7.69MM
First Award Date 09/15/00
Most Recent Award Date 09/01/15

Key Personnel

Last Name Name Awards Contact
Solen Kenneth A Solen 2
Mohammad Syed F Mohammad 4
Olsen Don B. Olsen 6
SUKAVANESHVAR SIVAPRASAD SUKAVANESHVAR 1

13 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: RFA-HL-14-011
Budget: 09/01/15 - 03/31/16

DESCRIPTION (provided by applicant): The timely diagnosis and optimal management of hemostatic dysfunction in trauma and surgical patients is challenging due to the unavailability of suitable analytical tools. The current need to conduct multiple tests with multiple blood samples on multiple devices to ascertain the specific nature of the hemos...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-280
Budget: 08/01/10 - 07/31/12

DESCRIPTION (provided by applicant): Improved understanding of the role of growth factors as biochemical mediators of wound healing has paved the way for a new family of bioactive therapeutic products to expedite wound healing. Delivery of growth factors (recombinant or as autologous platelets) has emerged as a possible commercial opportunity fo...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-280
Budget: 08/01/09 - 07/31/10

DESCRIPTION (provided by applicant): Improved understanding of the role of growth factors as biochemical mediators of wound healing has paved the way for a new family of bioactive therapeutic products to expedite wound healing. Delivery of growth factors (recombinant or as autologous platelets) has emerged as a possible commercial opportunity fo...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-80
Budget: 08/15/08 - 07/31/09

DESCRIPTION (provided by applicant): Improved understanding of the role of growth factors as biochemical mediators of wound healing has paved the way for a new family of bioactive therapeutic products to expedite wound healing. Delivery of growth factors (recombinant or as autologous platelets) has emerged as a possible commercial opportunity fo...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-04-28
Budget: 07/01/07 - 06/30/08

DESCRIPTION (provided by applicant): Coronary heart disease (CHD) and stroke remain 1 of the major causes of morbidity and mortality in the US, and platelets play a major role in CHD/stroke. Thus, the use of antiplatelet drugs is helpful in the prevention or treatment of such vascular disorders. Despite routine use of antiplatelet agents in a la...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-04-28
Budget: 07/01/06 - 06/30/07

DESCRIPTION (provided by applicant): Coronary heart disease (CHD) and stroke remain 1 of the major causes of morbidity and mortality in the US, and platelets play a major role in CHD/stroke. Thus, the use of antiplatelet drugs is helpful in the prevention or treatment of such vascular disorders. Despite routine use of antiplatelet agents in a la...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-04-28
Budget: 07/01/05 - 06/30/06

DESCRIPTION (provided by applicant): Coronary heart disease (CHD) and stroke remain 1 of the major causes of morbidity and mortality in the US, and platelets play a major role in CHD/stroke. Thus, the use of antiplatelet drugs is helpful in the prevention or treatment of such vascular disorders. Despite routine use of antiplatelet agents in a la...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/16/04 - 08/15/06

DESCRIPTION (provided by applicant): Anticoagulation of blood is necessary for prevention of clotting and/or thromboembolism during cardiopulmonary bypass or other procedures that require extracorporeal circulation. Conventionally, anticoagulation is achieved by administering heparin and reversed by neutralizing heparin with protamine. Both of t...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/15/03 - 08/15/04

DESCRIPTION (provided by applicant): Anticoagulation of blood is necessary for prevention of clotting and/or thromboembolism during cardiopulmonary bypass or other procedures that require extracorporeal circulation. Conventionally, anticoagulation is achieved by administering heparin and reversed by neutralizing heparin with protamine. Both of t...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/01/02 - 07/31/03

DESCRIPTION (Verbatim From Applicant's Abstract):This phase II application is for further development, optimization, and clinical testing of a platelet function assay called the light scattering whole blood aggregometer (LSWBA). The concept of utilizing differential light scattering for the detection of platele...

Load More